Merck Sees “Unprecedented” Growth in Gardasil Vaccine – Over $3 Billion in Sales in 2018 with Expansion into China
Vaccine manufacturer Merck & Co. has reported earnings from its Gardasil HPV vaccine for 2018 at $3.15 billion, far above the previous year sales of $2.31 billion. First quart of 2019 sales of the Gardasil vaccine have soared 31% to $838 million for the first three months of 2019. Executives from the company have stated that these sales of the Gardasil vaccine are "unprecedented," and the company plans to spend over $1 billion to expand its Gardasil vaccine production. Much of this growth of the Gardasil vaccine market is due to Merck's expansion into China. While many other countries, like Japan, are pulling back on their recommendations for the Gardasil vaccines due to the sheer volume of reported Gardasil vaccine injuries, and the resulting lawsuits in those countries against Merck and its distributors, something that is not possible in the United States due to the legal immunity vaccine makers enjoy, China is running full speed ahead to introduce the Gardasil vaccine to its population.